647-655
Mini Review
Temozolomide in malignant gliomas: current use and future targets
J. Lee Villano, Tara E. Seery and Linda R. Bressler
657-663
Original Article
Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study
Jeeyun Lee, Kyung Hae Jung, Young Suk Park, Joong Bae Ahn and Sang Jun Shin, et al.
665-672
Original Article
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study
Mark P. Saunders, Richard Wilson, Marc Peeters, Robert Smith and Alex Godwood, et al.
673-680
Original Article
Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer
Franco Nolè, D. Crivellari, R. Mattioli, G. Pinotti and P. Foa, et al.
681-689
Original Article
The microtubule-active antitumor compound TTI-237 has both paclitaxel-like and vincristine-like properties
Carl F. Beyer, Nan Zhang, Richard Hernandez, Danielle Vitale and Thai Nguyen, et al.
691-706
Original Article
Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species
Joshua Ö. Haznedar, Shem Patyna, Carlo L. Bello, Geoffrey W. Peng and William Speed, et al.
707-713
Original Article
Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer
Gyeong-Won Lee, Hye Jung Kim, Ji-Hyun Ju, Seok-Hyun Kim and Hoon Gu Kim, et al.
715-721
Original Article
Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of γ-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells
Takeshi Asano, Arisa Tsutsuda-Asano and Yoshitaka Fukunaga
723-732
Original Article
SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples
Andrew Conroy, David E. Stockett, Duncan Walker, Michelle R. Arkin and Ute Hoch, et al.
733-740
Original Article
Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma
Pooja Hingorani, Wendong Zhang, Sajida Piperdi, Leyna Pressman and Juan Lin, et al.
741-751
Original Article
Open AccessCharacterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine
Charles O. Noble, Zexiong Guo, Mark E. Hayes, James D. Marks and John W. Park, et al.
753-761
Original Article
Molecular hydrogen alleviates nephrotoxicity induced by an anti-cancer drug cisplatin without compromising anti-tumor activity in mice
Naomi Nakashima-Kamimura, Takashi Mori, Ikuroh Ohsawa, Sadamitsu Asoh and Shigeo Ohta
763-768
Original Article
A randomized, placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar (LY335979) in women with metastatic or locally recurrent breast cancer who have received one prior chemotherapy regimen
Paul Ruff, D. A. Vorobiof, J. P. Jordaan, G. S. Demetriou and S. D. Moodley, et al.
769-775
Original Article
Open AccessFotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Alba A. Brandes, A. Tosoni, E. Franceschi, V. Blatt and A. Santoro, et al.
777-783
Original Article
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer
Ramesh K. Ramanathan, Chandra P. Belani, Deepti A. Singh, Michael Tanaka and Heinz-Josef Lenz, et al.
785-791
Original Article
A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer
Vasiliki Bozionelou, Kostas Kalbakis, Lambros Vamvakas, Sofia Agelaki and Nikolaos Androulakis, et al.
793-802
Original Article
Pro-apoptotic and cytostatic activity of naturally occurring cardenolides
Elena Bloise, Alessandra Braca, Nunziatina De Tommasi and Maria Antonietta Belisario
803-810
Original Article
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors
Anna C. Pavlick, Jennifer Wu, John Roberts, Mark A. Rosenthal and Anne Hamilton, et al.
811-827
Original Article
Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts
Vilma A. Sardão, Paulo J. Oliveira, Jon Holy, Catarina R. Oliveira and Kendall B. Wallace
829-835
Original Article
Open AccessCarbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents
Lee Roy Morgan, Robert F. Struck, William R. Waud, Blaise LeBlanc and Andrew H. Rodgers, et al.
837-845
Original Article
Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane
Sabry M. Attia, Alaa A. Al-Anteet, Nouf M. Al-Rasheed, Abdulqader A. Alhaider and Mohammed M. Al-harbi
847-856
Original Article
Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity
Johnson J. Liu, Stephen M. F. Jamieson, Joshuan Subramaniam, Virginia Ip and Nancy N. Jong, et al.
857-860
Short Communication
Intestinal perforation associated with rituximab therapy for post-transplant lymphoproliferative disorder after liver transplantation
Agustin Cornejo, Mary Bohnenblust, Catherine Harris and Gregory A. Abrahamian
861-862
Letter to the Editor
MTT assays can underestimate cell numbers
Wai M. Liu and Angus G. Dalgleish